» Articles » PMID: 17949898

Phospholipase D Provides a Survival Signal in Human Cancer Cells with Activated H-Ras or K-Ras

Overview
Journal Cancer Lett
Specialty Oncology
Date 2007 Oct 24
PMID 17949898
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Phospholipase D (PLD) is elevated in rodent fibroblasts expressing activated H-Ras mutants. We therefore examined the PLD activity in human cancer cells with activating Ras mutations. T24 bladder carcinoma cells express an activated H-Ras gene and Calu-1 lung carcinoma cells express an activated K-Ras gene. We report here that both of these cancer cell lines express highly elevated levels of PLD activity and that the PLD activity is dependent upon Ras. We also show that the PLD activity is dependent upon the Ras effector molecules RalA and phosphatidylinositol-3-kinase (PI3K). PLD activity has been shown to provide a survival signal in breast cancer cell lines that suppressed stress-induced apoptosis. Suppression of PLD activity in the T24 and Calu-1 cells resulted in apoptotic cell death in the absence of serum, indicating that the elevated PLD activity provided a survival signal in these cancer cell lines. Suppression of Ras, RalA, or PI3K also led to apoptosis in the absence of serum. These data indicate that a critical component of Ras signaling in human cancer cells is the activation of PLD and that targeting PLD survival signals in cancer cells could be an effective strategy to induce apoptosis in human cancers with activating Ras mutations.

Citing Articles

The p53/ZEB1-PLD3 feedback loop regulates cell proliferation in breast cancer.

Liu B, Sun N, Lin H, Zhou X, Ma H, Wang X Cell Death Dis. 2023; 14(11):751.

PMID: 37978168 PMC: 10656518. DOI: 10.1038/s41419-023-06271-4.


Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches.

Salucci S, Aramini B, Bartoletti-Stella A, Versari I, Martinelli G, Blalock W Cancers (Basel). 2023; 15(12).

PMID: 37370855 PMC: 10296511. DOI: 10.3390/cancers15123245.


Synthetic Vulnerabilities in the KRAS Pathway.

Roman M, Hwang E, Sweet-Cordero E Cancers (Basel). 2022; 14(12).

PMID: 35740503 PMC: 9221492. DOI: 10.3390/cancers14122837.


NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Laskin J, Liu S, Tolba K, Heining C, Schlenk R, Cheema P Ann Oncol. 2020; 31(12):1693-1703.

PMID: 32916265 PMC: 8911318. DOI: 10.1016/j.annonc.2020.08.2335.


Mammalian phospholipase D: Function, and therapeutics.

McDermott M, Wang Y, Wakelam M, Bankaitis V Prog Lipid Res. 2019; 78:101018.

PMID: 31830503 PMC: 7233427. DOI: 10.1016/j.plipres.2019.101018.


References
1.
Jiang H, Luo J, Urano T, Frankel P, Lu Z, Foster D . Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature. 1995; 378(6555):409-12. DOI: 10.1038/378409a0. View

2.
Foster D . Regulation of mTOR by phosphatidic acid?. Cancer Res. 2007; 67(1):1-4. DOI: 10.1158/0008-5472.CAN-06-3016. View

3.
Chen Y, Zheng Y, Foster D . Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 2003; 22(25):3937-42. DOI: 10.1038/sj.onc.1206565. View

4.
Rodrik V, Gomes E, Hui L, Rockwell P, Foster D . Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett. 2006; 580(24):5647-52. PMC: 1876739. DOI: 10.1016/j.febslet.2006.09.013. View

5.
Fang Y, Bachmann R, Flanigan A, Chen J . Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001; 294(5548):1942-5. DOI: 10.1126/science.1066015. View